Glaxo respiratory approvals could bump production at Advair plant; Pharma steps up in Indian HIV/AIDS drug shortage;

@FiercePharma: Top-read news this weekend: Bayer resolves 200 Trasylol lawsuits. Article | Follow @FiercePharma

@EricPFierce: EU official says hunting wild boar may be spreading African swine fever. Wants it stopped. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI: Novartis employee pleads guilty to bribery in Poland. Story | Follow @CarlyHFierce

> GlaxoSmithKline's ($GSK) recent FDA approvals could spell a production increase at its Zebulon, NC, plant. More

> Amid dwindling supply in India, Indian companies and global health groups have ramped up efforts to provide tenofovir/lamivudine tablets for the country's free HIV/AIDS drug program. Report

> Healthcare group BTG plans to start selling two of its oncology treatments directly to 11 European countries, beginning next April. More

> New analysis of Celgene's ($CELG) ESTEEM 2 trial demonstrated that more than 70% of patients who received treatment with psoriasis drug Otezla twice-daily after 16 weeks achieved clinically meaningful improvement. Report

> Alexion Pharmaceuticals ($ALXN) has named Leonard Bell the chairman of its board. Report

Medical Device News

@FierceMedDev: ICYMI Friday: Deerfield bets up to $125M on nuclear materials used in imaging. Article | Follow @FierceMedDev

@VarunSaxena2: Report warns of cyberattacks against medical devices to extort money. More | Follow @VarunSaxena2

[No ads for editors]

@EmilyWFierce: Device from Bay Area startup detects microRNA in blood to screen for dozens of cancers. Story via Wired | Follow @EmilyWFierce

@MichaelGFierce: With Roche's Herceptin, green tea component doubles drug accumulation in cancer cells. FierceDrugDelivery story | Follow @MichaelGFierce

> PAD patients gain another treatment option as the FDA approves its first drug-coated balloon. Story

> Harvard scientists develop super-repellent coating technology for commonly used devices. Report

Biotech News

@FierceBiotech: 2014's most successful biotech IPOs. Special report | Follow @FierceBiotech

@JohnCFierce: ICYMI: Gilead wins FDA approval for its hep C combo pill, a blockbuster in the making. Article | Follow @JohnCFierce

@DamianFierce: And finally, wins FDA approval for Harvoni. Release | Follow @DamianFierce

@EmilyMFierce: What It's Like to Carry Your Nobel Prize through Airport Security. Article from Scientific American | Follow @EmilyMFierce

> Smith & Nephew hit by setback as PhIII regenerative med study flops. Story

> Pfizer nabs a fast FDA review for breast cancer pipeline star palbociclib. More

> MGH investigator Tanzi says breakthrough will 'revolutionize' Alzheimer's R&D. Article

CRO News

> Catalent reaches out to lung cancer patients with research agreement. Item

> Covance and Novartis team up with eyes on Big Data. Article

> Parexel expands in the U.K. after an eClinical buyout. Story

> Clinipace raises $4M after staging 5 buyouts in 5 years. More

> With help from Charles River, AstraZeneca expands its respiratory pipeline. Report

Biotech IT News

> Merck's VC unit invests in data security business. More

> ISB teams with Google for NCI Cancer Genomics Cloud project. Report

> NIH turns on Big Data funding faucet. Story

> Merck and Pfizer join Accenture's Life Sciences Cloud Coalition. News

> VC shop follows Y Combinator into the world of biotech incubators. Article

Animal Health News

> Chronic wasting disease found in Iowa captive deer population. Item

> U.K.'s Pirbright Institute tabbed for $29M in funding to train vet scientists. More

> Pan Genome Systems searching for money to fund new Johne's disease vaccine. Article

> UC Davis researchers solve century-old bluetongue virus mystery. Story

> Three European companies will team to develop VLP vaccines for vet use. Report

And Finally... Frozen fecal matter that's swallowed like a pill appears effective against C. difficile, a recurring and sometimes deadly bacterial infection, a new study says. More

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.